Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Weber on Growing Costs With Triplet and Four-Drug Regimens in Melanoma

Jeffrey S. Weber, MD, PhD
Published: Tuesday, Jan 16, 2018



Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

Weber attests to the advances that have been made in triplet and four-drug regimens, discussing a clinical trial combining ipilimumab (Yervoy) and nivolumab (Opdivo) with a histone deacetylase inhibitor as an example. It is possible that flipping the dose levels and adjusting the schedule so there is no prohibitive toxicity will lead to the implementation of triplets in immunotherapy.

According to Weber, though trials such as these appear promising, there are financial toxicities with these systemic therapies that pose a major deterrent to these trials’ progress and application in mainstream medicine.

Though Weber sheds light on the potential of these trials, he also acknowledges the increasing costs of drugs, which could lead to greater issues in healthcare in the future.


Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

Weber attests to the advances that have been made in triplet and four-drug regimens, discussing a clinical trial combining ipilimumab (Yervoy) and nivolumab (Opdivo) with a histone deacetylase inhibitor as an example. It is possible that flipping the dose levels and adjusting the schedule so there is no prohibitive toxicity will lead to the implementation of triplets in immunotherapy.

According to Weber, though trials such as these appear promising, there are financial toxicities with these systemic therapies that pose a major deterrent to these trials’ progress and application in mainstream medicine.

Though Weber sheds light on the potential of these trials, he also acknowledges the increasing costs of drugs, which could lead to greater issues in healthcare in the future.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x